Expression of PD-1 is up-regulated in CD4+CD25+ FoxP3+ regulatory T cell of non-responders after hepatitis B surface antigen vaccine immunization

Clinical Immunology

Volumn 129, Issue 1, 2008, Pages 176-177

  Yang, Zhao ^a,b   Zhang, JingBo ^b   Wang, Li ^a   Wu, YuZhang ^a   Wang, Shuguang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Xinqiao Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PROGRAMMED CELL DEATH 1 MOLECULE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APOPTOSIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL TRANSPLANTATION; CHINA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LETTER; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 51449090739     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.07.007     Document Type: Letter

References (18)

1. Craven D.E., Awdeh Z.L., Kunches L.M., Yunis E.J., Dienstag J.L., Werner B.G., Polk B.F., Syndman D.R., Platt R., and Crumpacker C.S. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann. Intern. Med. 105 (1986) 356-360
2. Lemon S.M., and Thomas D.L. Vaccines to prevent viral hepatitis. N. Engl. J. Med. 336 (1997) 196-204
3. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Alter H.J., Taylor P.E., DeVera A., Chen G.T., and Kellner A. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N. Engl. J. Med. 307 (1982) 1481-1486
4. Yang Z., Wang L., Niu W., Wu Y., Zhang J., and Meng G. Increased CD4+CD25+FoxP3+ regulatory T cells in the blood of nonresponders after standard hepatitis B surface antigen vaccine immunization. Clin. Immunol. 127 (2008) 265-266
5. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 (2000) 455-458
6. Morse M.A., Clay T.M., Mosca P., and Lyerly H.K. Immunoregulatory T cells in cancer immunotherapy. Expert Opin. Biol. Ther. 2 (2002) 827-834
7. Piccirillo C.A., and Shevach E.M. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J. Immunol. 167 (2001) 1137-1140
8. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., Kaiser L.R., and June C.H. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168 (2002) 4272-4276
9. Lim H.W., Hillsamer P., Banham A.H., and Kim C.H. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J. Immunol. 175 (2005) 4180-4183
10. Lim H.W., Hillsamer P., and Kim C.H. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J. Clin. Invest. 114 (2004) 1640-1649
11. Yang Z., Wang L., Niu W., Wu Y., Zhang J., and Meng G. Increased CD4+CD25+FoxP3+ regulatory T cells in the blood of nonresponders after standard hepatitis B surface antigen vaccine immunization. Clin. Immunol. 127 (2008) 265-266
12. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev., Immunol. 4 (2004) 336-347
13. Probst H.C., McCoy K., Okazaki T., Honjo T., and van den B.M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6 (2005) 280-286
14. Ito T., Ueno T., Clarkson M.R., Yuan X., Jurewicz M.M., Yagita H., Azuma M., Sharpe A.H., Auchincloss Jr. H., Sayegh M.H., and Najafian N. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J. Immunol. 174 (2005) 6648-6656
15. Sandner S.E., Clarkson M.R., Salama A.D., Sanchez-Fueyo A., Domenig C., Habicht A., Najafian N., Yagita H., Azuma M., Turka L.A., and Sayegh M.H. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 174 (2005) 3408-3415
16. Schilbach K., Schick J., Wehrmann M., Wollny G., Simon P., Schlegel P.G., and Eyrich M. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers. Transplantation 84 (2007) 214-222
17. Kitazawa Y., Fujino M., Wang Q., Kimura H., Azuma M., Kubo M., Abe R., and Li X.K. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 83 (2007) 774-782
18. Polanczyk M.J., Hopke C., Vandenbark A.A., and Offner H. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int. Immunol. 19 (2007) 337-343